Evidence map›Paper›PMID 42159696›Full record

ArticleDiabetologia2026

Human islet amyloid polypeptide aggregation upregulates the mitochondrial cholesterol transport protein StAR and induces mitochondrial dysfunction in beta cells.

Meghan F Hogan, Rehana Akter, Alfred C Aplin, Andrew T Templin, Nathalie Esser, Daniel T Meier, Brendy-Sue Fountaine, Joseph J Castillo, Assam El-Osta, Rebecca L Hull-Meichle and 2 more

Abstract read
In one paragraph

Article in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Meghan F Hogan *VA Puget Sound Health Care System, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-5767-1599
Rehana Akter *VA Puget Sound Health Care System, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-6922-350X
Alfred C AplinVA Puget Sound Health Care System, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-3346-9484
Andrew T TemplinVA Puget Sound Health Care System, Seattle, WA, USA. templin@iu.edu.ORCID http://orcid.org/0000-0002-6241-9304
Nathalie EsserVA Puget Sound Health Care System, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-1823-3817
Daniel T MeierVA Puget Sound Health Care System, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-3348-4657
Brendy-Sue FountaineVA Puget Sound Health Care System, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-7936-471X
Joseph J CastilloVA Puget Sound Health Care System, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-4080-2545
Assam El-OstaEpigenetics in Human Health and Disease Program, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-7968-7375
Rebecca L Hull-MeichleVA Puget Sound Health Care System, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-9690-4087
Sakeneh ZraikaVA Puget Sound Health Care System, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-4831-7034
Steven E KahnVA Puget Sound Health Care System, Seattle, WA, USA. skahn@uw.edu.ORCID http://orcid.org/0000-0001-7307-9002

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 1986 to 2026
$41.4M
Diabetes, Obesity and Metabolism Training ProgramT32DK007247 · NIDDK · UNIVERSITY OF WASHINGTON · PI GREGORY J MORTON, KRISTINA Marie UTZSCHNEIDER · 1986 to 2026
$10.0M
Nutrition, Obesity and Atherosclerosis Training ProgramT32HL007028 · NHLBI · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 1985 to 2026
$6.4M
Islet Endothelial Dysfunction in DiabetesR01DK088082 · NIDDK · SEATTLE INST FOR BIOMEDICAL/CLINICAL RES · PI HULL-MEICHLE, REBECCA LUCY · 2010 to 2020
$2.8M
Effects of Cholesterol in Pancreatic IsletsR01DK134502 · NIDDK · SEATTLE INST FOR BIOMEDICAL/CLINICAL RES · PI Sakeneh Zraika · 2023 to 2026
$1.6M
The Role of Apoptosis Repressor with Caspase Recruitment Domain (ARC) in Amyloid-Induced Beta-cell ApoptosisF32DK107022 · NIDDK · UNIVERSITY OF WASHINGTON · PI TEMPLIN, ANDREW T. · 2015 to 2018
$171k
American Diabetes Association 1-18-PDF-174Belgian American Educational Foundation Postdoctoral FellowshipBLRD VA I01 BX001060BLRD VA I01 BX006913BLRD VA IK2 BX004659French Society of Diabetes Young Francophone Researcher Postdoctoral FellowshNational Health and Medical Research Council 0526681National Health and Medical Research Council 1154650NHLBI NIH HHS T32 HL007028NIDDK NIH HHS F32 DK107022NIDDK NIH HHS P30 DK017047NIDDK NIH HHS R01 DK088082NIDDK NIH HHS R01 DK134502NIDDK NIH HHS T32 DK007247NIH HHS DK007247NIH HHS DK017047NIH HHS DK088082NIH HHS DK107022NIH HHS DK134502NIH HHS HL007028University of Washington DickUniversity of Washington Julia McAbee Endowed Fellowship in Diabet
6 · The paper itself

Abstract

aims/hypothesisLoss of islet beta cell function and mass are critical in the pathogenesis of type 2 diabetes, a disease in which ~90% of individuals exhibit islet amyloid deposition. Amyloid deposits comprise the normal beta cell secretory product, human islet amyloid polypeptide (hIAPP), the aggregation of which is toxic to beta cells. While the underlying mechanism(s) for toxicity remain unknown, it is likely to involve mitochondrial dysfunction. We have shown that the mitochondrial cholesterol transport protein, steroidogenic acute regulatory protein (StAR), is upregulated in beta cells following amyloid deposition. Here, we examined the role of StAR in the toxicity of islet amyloidosis.

methodsHuman islets from non-diabetic donors were cultured under amyloidogenic conditions and StAR expression was examined. StAR expression was also determined in islets isolated from transgenic mice expressing amyloidogenic hIAPP or non-transgenic littermates expressing non-amyloidogenic islet amyloid polypeptide, cultured under amyloidogenic conditions with or without the addition of an amyloid inhibitor. Total islet cholesterol content, mitochondrial cholesterol content, mitochondrial function and cell viability/death were compared in transgenic hIAPP and non-transgenic islets cultured in amyloidogenic conditions. Additionally, StAR localisation to islet cells, as well as its intracellular localisation, was examined.

resultsStAR was present in human islets at the mRNA and protein level, and expression increased significantly with amyloid formation in vitro. Further, in hIAPP transgenic mouse islets, StAR expression was amyloid-dependent. StAR was predominantly expressed in beta cells, and the amyloid-induced increase in StAR protein was found specifically in the mitochondrial fraction. While total and mitochondrial cholesterol content was unchanged between non-transgenic and hIAPP transgenic mouse islets cultured under amyloidogenic conditions, increased StAR expression was associated with decreased mitochondrial glucose-stimulated respiration and increased cell death. CONCLUSIONS/

interpretationThese findings are consistent with StAR having a pathophysiological role in the beta cell in type 2 diabetes, where its upregulation under conditions of islet amyloid deposition could contribute to mitochondrial dysfunction.

Indexed as

Insulin-Secreting CellsIslet Amyloid PolypeptideMitochondriaPhosphoproteinsAnimalsCells, CulturedCholesterolHumansIslets of LangerhansMiceMice, TransgenicSteroidogenic Acute Regulatory ProteinUp-RegulationCholesterolIslet Amyloid PolypeptidePhosphoproteinsSteroidogenic Acute Regulatory ProteinAmyloidBeta cellCholesterolIslet amyloid polypeptideMitochondrial cholesterol transport proteinMitochondrial dysfunctionStARSTARD1Type 2 diabetes

Identifiers

PMID42159696
PMCPMC13310199

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.